Literature DB >> 19822224

Comparative performance of the REGA subtyping tool version 2 versus version 1.

Ana B Abecasis1, Yunpeng Wang, Pieter Libin, Stijn Imbrechts, Tulio de Oliveira, Ricardo J Camacho, Anne-Mieke Vandamme.   

Abstract

The REGA HIV-1 subtyping tool is a phylogenetic-based method for subtyping HIV-1 genomic sequences that was published in 2005. The subtyping tool combines phylogenetic approaches with recombination detection methods. Recently, version 2 was released (http://www.bioafrica.net/rega-genotype/html/index.html) as an improvement of version 1. Version 2 implements a Decision-Tree-based algorithm that was not implemented in version 1. We wanted to compare the two versions on a large sequence dataset to assess the improvements of version 2 and to verify whether features lost during updating the tool needed to be recovered. We analysed the results of the two versions in the genotyping of 4676 HIV-1 pol sequences. We compared those results to a manual approach, used in previous studies. Our results show that version 2 has an overall better sensitivity but especially for the detection of subtypes A, B, D, F, G and CRF14_BG and CRF06_CPX. For the other subtypes, no significant differences were observed in the sensitivity of versions 1 and 2. The overall increase in sensitivity was however accompanied by a decrease in the specificity for the detection of subtype B. This is the main limitation of version 2. However, while the number of false negatives decreased by 53 samples, the number of false positives increased only by 5 samples from version 1 to 2. The performance of the REGA HIV-1 subtyping tool was considerably improved from one version to the other. Our results are very valuable and allow us to make suggestions for further improvement of the tool for a version 3 release. 2009 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19822224     DOI: 10.1016/j.meegid.2009.09.020

Source DB:  PubMed          Journal:  Infect Genet Evol        ISSN: 1567-1348            Impact factor:   3.342


  8 in total

1.  Chronology and evolution of the HIV-1 subtype C epidemic in Ethiopia.

Authors:  Damien C Tully; Charles Wood
Journal:  AIDS       Date:  2010-06-19       Impact factor: 4.177

2.  Frequent emergence of N348I in HIV-1 subtype C reverse transcriptase with failure of initial therapy reduces susceptibility to reverse-transcriptase inhibitors.

Authors:  Jessica H Brehm; Dianna L Koontz; Carole L Wallis; Kathleen A Shutt; Ian Sanne; Robin Wood; James A McIntyre; Wendy S Stevens; Nicolas Sluis-Cremer; John W Mellors
Journal:  Clin Infect Dis       Date:  2012-05-22       Impact factor: 9.079

3.  HIV-1 subtype distribution in the Gambia and the significant presence of CRF49_cpx, a novel circulating recombinant form.

Authors:  Thushan I de Silva; Roxanne Turner; Stéphane Hué; Roochi Trikha; Carla van Tienen; Clayton Onyango; Assan Jaye; Brian Foley; Hilton Whittle; Sarah L Rowland-Jones; Matthew Cotten
Journal:  Retrovirology       Date:  2010-10-09       Impact factor: 4.602

4.  Potent autologous and heterologous neutralizing antibody responses occur in HIV-2 infection across a broad range of infection outcomes.

Authors:  Thushan I de Silva; Marlén Aasa-Chapman; Matthew Cotten; Stéphane Hué; James Robinson; Frederic Bibollet-Ruche; Ramu Sarge-Njie; Neil Berry; Assan Jaye; Peter Aaby; Hilton Whittle; Sarah Rowland-Jones; Robin Weiss
Journal:  J Virol       Date:  2011-11-09       Impact factor: 5.103

5.  Zidovudine (AZT) monotherapy selects for the A360V mutation in the connection domain of HIV-1 reverse transcriptase.

Authors:  Jessica H Brehm; Yanille Scott; Dianna L Koontz; Steven Perry; Scott Hammer; David Katzenstein; John W Mellors; Nicolas Sluis-Cremer
Journal:  PLoS One       Date:  2012-02-21       Impact factor: 3.240

6.  The effects of HIV-1 subtype and ethnicity on the rate of CD4 cell count decline in patients naive to antiretroviral therapy: a Canadian-European collaborative retrospective cohort study.

Authors:  Marina B Klein; Jim Young; David Dunn; Bruno Ledergerber; Caroline Sabin; Alessandro Cozzi-Lepri; Francois Dabis; Richard Harrigan; Darrell H Tan; Sharon Walmsley; John Gill; Curtis Cooper; Alexandra U Scherrer; Amanda Mocroft; Robert S Hogg; Fiona Smaill
Journal:  CMAJ Open       Date:  2014-10-01

7.  HIV-1 subtype distribution and its demographic determinants in newly diagnosed patients in Europe suggest highly compartmentalized epidemics.

Authors:  Ana B Abecasis; Annemarie M J Wensing; Dimitris Paraskevis; Jurgen Vercauteren; Kristof Theys; David A M C Van de Vijver; Jan Albert; Birgitta Asjö; Claudia Balotta; Danail Beshkov; Ricardo J Camacho; Bonaventura Clotet; Cillian De Gascun; Algis Griskevicius; Zehava Grossman; Osamah Hamouda; Andrzej Horban; Tatjana Kolupajeva; Klaus Korn; Leon G Kostrikis; Claudia Kücherer; Kirsi Liitsola; Marek Linka; Claus Nielsen; Dan Otelea; Roger Paredes; Mario Poljak; Elisabeth Puchhammer-Stöckl; Jean-Claude Schmit; Anders Sönnerborg; Danika Stanekova; Maja Stanojevic; Daniel Struck; Charles A B Boucher; Anne-Mieke Vandamme
Journal:  Retrovirology       Date:  2013-01-14       Impact factor: 4.602

8.  Limited cross-border infections in patients newly diagnosed with HIV in Europe.

Authors:  Dineke Frentz; Annemarie M J Wensing; Jan Albert; Dimitrios Paraskevis; Ana B Abecasis; Osamah Hamouda; Louise B Jørgensen; Claudia Kücherer; Daniel Struck; Jean-Claude Schmit; Birgitta Åsjö; Claudia Balotta; Danail Beshkov; Ricardo J Camacho; Bonaventura Clotet; Suzie Coughlan; Stéphane De Wit; Algirdas Griskevicius; Zehava Grossman; Andrzej Horban; Tatjana Kolupajeva; Klaus Korn; Leondios G Kostrikis; Kirsi Liitsola; Marek Linka; Claus Nielsen; Dan Otelea; Roger Paredes; Mario Poljak; Elisabeth Puchhammer-Stöckl; Anders Sönnerborg; Danica Stanekova; Maja Stanojevic; Anne-Mieke Vandamme; Charles A B Boucher; David A M C Van de Vijver
Journal:  Retrovirology       Date:  2013-04-03       Impact factor: 4.602

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.